- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Natco Pharma Ltd. (NATP)
Track the Natco Pharma share price today and view real-time NATP share price data, including charts, technicals, and key financials. View the NATP premarket stock price ahead of the market session or assess the after hours quote. Explore NATP stock price movements, trading volume, and market activity across the NSE exchange.
What Is the Natco Pharma Stock Price Today?
The Natco Pharma stock price today is 810.45.
What Is the Stock Symbol for Natco Pharma?
The stock symbol for Natco Pharma is ""NATP.""
What Stock Exchange Does Natco Pharma Trade On?
Natco Pharma is listed and trades on the NSE stock exchange.
Is Natco Pharma a Good Stock to Buy?
Determining whether Natco Pharma or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NATP quote. (ISIN: INE987B01026)
What Is the Natco Pharma Stock Price Today?
The Natco Pharma stock price today is 810.45.
What Is the Stock Symbol for Natco Pharma?
The stock symbol for Natco Pharma is ""NATP.""
What Stock Exchange Does Natco Pharma Trade On?
Natco Pharma is listed and trades on the NSE stock exchange.
Is Natco Pharma a Good Stock to Buy?
Determining whether Natco Pharma or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NATP quote. (ISIN: INE987B01026)
810.45
+1.65(+0.20%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
780.00
819.25
52 wk Range
773.60
1,226.80
Earnings results expected tomorrow
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
780.00819.25
52 wk Range
773.601,226.80
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
NATCOPHARM Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Neutral
Price Target
1,004.44
Upside
+23.94%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Strong Buy
Analyst Ratings
5 Buy
3 Hold
3 Sell
Ratings:
11 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 1,004.44
(+23.94% Upside)
Natco Pharma Ltd. Earnings Call Summary for Q2/2027
- NATCO raised FY27 PAT guidance to INR 775-800 crore from INR 700-750 crore despite 30.3% YoY revenue decline driven by lenalidomide erosion.
- Q2 revenue rose 28.4% sequentially to INR 1,019.4 crore; EBITDA margin held at 30.4% with company maintaining zero debt and INR 2,250 crore net cash.
- Management expects 10-15% growth in FY28, driven by upcoming launches including carfilzomib (first-to-file), trabectedin, olaparib, and Imbruvica.
- Brazil revenue surged 66% YoY to INR 121 crore; domestic business improved to INR 130-135 crore quarterly run rate with 15-20% annual growth expected.
- Shares traded flat at $808, near 52-week low, as investors remain cautious about transition from lenalidomide dependence to diversified product portfolio.
Last Updated: 13/11/2026, 10:38 pm
Read Full TranscriptEarnings
Latest Release
13/11/2026
EPS / Forecast
10.10 / 8.56
Revenue / Forecast
7.43B / 7.51B
Compare NATCOPHARM to Peers and Sector
Metrics to compare | NATCOPHARM | Peers Peers - average of corresponding metrics from companies closely matching NATCOPHARM: ALKEM, CIPLA, AUROPHARMA, GLENMARK, SUNPHARMA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNATCOPHARMPeersSector |
|---|---|---|---|---|
P/E Ratio | 13.9x | 41.0x | −0.2x | |
PEG Ratio | −0.43 | 0.56 | 0.00 | |
Price/Book | 1.7x | 4.4x | 2.6x | |
Price / LTM Sales | 4.6x | 4.7x | 2.8x | |
Upside (Analyst Target) | 22.7% | 12.0% | 61.2% | |
Fair Value Upside | Unlock | 0.6% | 9.7% | Unlock |
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Agrochemicals. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, fungicides, herbicides, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Natco Pharma (NATCOPHARM) Stock Price Today?
The Natco Pharma stock price today is 810.45 INR.
What Stock Exchange Does Natco Pharma Trade On?
Natco Pharma is listed and trades on the India National Stock Exchange.
What Is the Stock Symbol for Natco Pharma?
The stock symbol for Natco Pharma is "NATCOPHARM."
Does Natco Pharma Pay Dividends? What’s The Current Dividend Yield?
The Natco Pharma dividend yield is 0.6%%.
What Is the Natco Pharma Market Cap?
As of today, Natco Pharma market cap is 158.98B INR.
What Is Natco Pharma's Earnings Per Share (TTM)?
The Natco Pharma EPS (TTM) is 63.89.
From a Technical Analysis Perspective, Is NATCOPHARM a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has Natco Pharma Stock Split?
Natco Pharma has split 1 times.
How Many Employees Does Natco Pharma Have?
Natco Pharma has 4433 employees.
What is the current trading status of Natco Pharma (NATCOPHARM)?
As of 15/11/2026, Natco Pharma (NATCOPHARM) is trading at a price of 810.45 INR, with a previous close of 808.80 INR. The stock has fluctuated within a day range of 780.00 INR to 819.25 INR, while its 52-week range spans from 773.60 INR to 1,226.80 INR.
What Is Natco Pharma (NATCOPHARM) Price Target According to Analysts?
The average 12-month price target for Natco Pharma is 1,004.44 INR, with a high estimate of 1180 INR and a low estimate of 712 INR. 5 analysts recommend buying the stock, while 3 suggest selling, leading to an overall rating of Neutral. The stock has an +23.94% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.